Aptevo Therapeutics will present at the Society for Immunotherapy of Cancer to highlight its CD40-directed multispecific portfolio and platform technology designed to coordinate innate and adaptive immunity. This business update highlights the ce company's pipeline progress and remains relevant for investors monitoring clinical-stage immunotherapy developments.